Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of JZP-110 for excessive sleepiness in obstructive sleep apnea
NL-OMON44032Phase 3Active, not recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Mar 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of solriamfetol in obstructive sleep apnea hypopnea syndrome (OSAHS) (5 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Change in mean sleep latency on Maintenance of Wakefulness Test and Change in Epworth Sleepiness Scale score. Started Mar 2016; status: active, not recruiting.
02
Drugs
solriamfetol
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on NL-OMON44032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44032.